Therapeutic strategies for high-dose vasopressor-dependent shock

Estevão Bassi, Marcelo Park, Luciano Cesar Pontes Azevedo, Estevão Bassi, Marcelo Park, Luciano Cesar Pontes Azevedo

Abstract

There is no consensual definition of refractory shock. The use of more than 0.5 mcg/kg/min of norepinephrine or epinephrine to maintain target blood pressure is often used in clinical trials as a threshold. Nearly 6% of critically ill patients will develop refractory shock, which accounts for 18% of deaths in intensive care unit. Mortality rates are usually greater than 50%. The assessment of fluid responsiveness and cardiac function can help to guide therapy, and inotropes may be used if hypoperfusion signs persist after initial resuscitation. Arginine vasopressin is frequently used in refractory shock, although definite evidence to support this practice is still missing. Its associations with corticosteroids improved outcome in observational studies and are therefore promising alternatives. Other rescue therapies such as terlipressin, methylene blue, and high-volume isovolemic hemofiltration await more evidence before use in routine practice.

Figures

Figure 1
Figure 1
Suggested algorithm for high-dose vasopressor dependent shock. SvO2 = mixed venous oxygenation saturation; ScvO2 = superior vena cava oxygen saturation; PAC = pulmonary artery catheter; CI = cardiac index; HT = hematocrit; RBCs = red blood cell transfusions; GIK = glucose-insulin-potassium solution; AVP = arginin-vasopressin; ECMO = extracorporeal membrane oxygenation; MB = methylene blue. *See text for details.

References

    1. de Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine. 2010;362(9):779–789.
    1. Benbenishty J, Weissman C, Sprung CL, Brodsky-Israeli M, Weiss Y. Characteristics of patients receiving vasopressors. Heart and Lung. 2011;40(3):247–252.
    1. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. The New England Journal of Medicine. 2008;358(9):877–887.
    1. Jenkins CR, Gomersall CD, Leung P, Joynt GM. Outcome of patients receiving high dose vasopressor therapy: a retrospective cohort study. Anaesthesia and Intensive Care. 2009;37(2):286–289.
    1. Abid O, Akça S, Haji-Michael P, Vincent J-L. Strong vasopressor support may be futile in the intensive care unit patient with multiple organ failure. Critical Care Medicine. 2000;28(4):947–949.
    1. Castro R, Regueira T, Aguirre ML, et al. An evidence-based resuscitation algorithm applied from the emergency room to the ICU improves survival of severe septic shock. Minerva Anestesiologica. 2008;74(6):223–231.
    1. Park B-K, Shim T-S, Lim C-M, et al. The effects of methylene blue on hemodynamic parameters and cytokine levels in refractory septic shock. Korean Journal of Internal Medicine. 2005;20(2):123–128.
    1. Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107(18):2313–2319.
    1. Torgersen C, Dünser MW, Wenzel V, et al. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Medicine. 2010;36(1):57–65.
    1. Morelli A, Ertmer C, Lange M, et al. Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia. 2008;100(4):494–503.
    1. Leone M, Albanèse J, Delmas A, Chaabane W, Garnier F, Martin C. Terlipressin in catecholamine-resistant septic shock patients. Shock. 2004;22(4):314–319.
    1. Brown SM, Lanspa MJ, Jones JP, et al. Survival after shock requiring high-dose vasopressor therapy. Chest. 2013;143(3):664–671.
    1. Torgersen C, Luckner G, Schröder DCH, et al. Concomitant arginine-vasopressin and hydrocortisone therapy in severe septic shock: association with mortality. Intensive Care Medicine. 2011;37(9):1432–1437.
    1. Luckner G, Dünser MW, Jochberger S, et al. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Critical Care Medicine. 2005;33(11):2659–2666.
    1. Dünser MW, Mayr AJ, Ulmer H, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesthesia and Analgesia. 2001;93(1):7–13.
    1. Mayr VD, Dünser MW, Greil V, et al. Causes of death and determinants of outcome in critically ill patients. Critical Care. 2006;10(6, article R154)
    1. Kumar A, Zarychanski R, Light B, et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Critical Care Medicine. 2010;38(9):1773–1785.
    1. Maizel J, Airapetian N, Lorne E, Tribouilloy C, Massy Z, Slama M. Diagnosis of central hypovolemia by using passive leg raising. Intensive Care Medicine. 2007;33(7):1133–1138.
    1. Arsura EL, Kilgore WB, Strategos E. Purulent pericarditis misdiagnosed as septic shock. Southern Medical Journal. 1999;92(3):285–288.
    1. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical Care Medicine. 2006;34(6):1589–1596.
    1. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. Journal of the American Medical Association. 2006;295(21):2511–2515.
    1. Miller GA, Sutton GC, Kerr IH, Gibson RV, Honey M. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. British Medical Journal. 1971;2(5763):681–684.
    1. Landry DW, Oliver JA. Mechanisms of disease: the pathogenesis of vasodilatory shock. The New England Journal of Medicine. 2001;345(8):588–595.
    1. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation. 2003;107(24):2998–3002.
    1. Thiemermann C, Szabó C, Mitchell JA, Vane JR. Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. Proceedings of the National Academy of Sciences of the United States of America. 1993;90(1):267–271.
    1. Levy B, Collin S, Sennoun N, et al. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Medicine. 2010;36(12):2019–2029.
    1. Zanotti-Cavazzonia SL, Hollenberg SM. Cardiac dysfunction in severe sepsis and septic shock. Current Opinion in Critical Care. 2009;15(5):392–397.
    1. Crowell JW, Guyton AC. Evidence favoring a cardiac mechanism in irreversible hemorrhagic shock. American Journal of Physiology. 1961;201:893–896.
    1. Michard F, Boussat S, Chemla D, et al. Relation between respiratory changes in arterial pulse pressure and fluid responsiveness in septic patients with acute circulatory failure. American Journal of Respiratory and Critical Care Medicine. 2000;162(1):134–138.
    1. Lee AJ, Cohn JH, Ranasinghe JS. Cardiac output assessed by invasive and minimally invasive techniques. Anesthesiology Research and Practice. 2011;2011:17 pages.475151
    1. Feissel M, Michard F, Faller J-P, Teboul J-L. The respiratory variation in inferior vena cava diameter as a guide to fluid therapy. Intensive Care Medicine. 2004;30(9):1834–1837.
    1. Marik PE, Cavallazzi R, Vasu T, Hirani A. Dynamic changes in arterial waveform derived variables and fluid responsiveness in mechanically ventilated patients: a systematic review of the literature. Critical Care Medicine. 2009;37(9):2642–2647.
    1. Honore PM, Dellinger RP, Levy MM, et al. Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Critical Care Medicine. 2013;41(2):580–637.
    1. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. The New England Journal of Medicine. 2001;345(19):1368–1377.
    1. Jansen TC, van Bommel J, Schoonderbeek FJ, et al. Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2010;182(6):752–761.
    1. Hayes MA, Timmins AC, Yau EHS, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. The New England Journal of Medicine. 1994;330(24):1717–1722.
    1. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. The New England Journal of Medicine. 1995;333(16):1025–1032.
    1. Peyton PJ, Chong SW. Minimally invasive measurement of cardiac output during surgery and critical care: a meta-analysis of accuracy and precision. Anesthesiology. 2010;113(5):1220–1235.
    1. Lee AJ, Cohn JH, Ranasinghe JS. Cardiac output assessed by invasive and minimally invasive techniques. Anesthesiology Research and Practice. 2011;2011:17 pages.475151
    1. Ramsingh D, Alexander B, Cannesson M. Clinical review: does it matter which hemodynamic monitoring system is used? Critical Care. 2013;17(2):p. 208.
    1. Seif D, Perera P, Mailhot T, Riley D, Mandavia D. Bedside ultrasound in resuscitation and the rapid ultrasound in shock protocol. Critical Care Research and Practice. 2012;2012:14 pages.503254
    1. Sprung CL, Goodman S, Weiss YG. Steroid therapy of septic shock. Critical Care Clinics. 2009;25(4):825–834.
    1. Annane D, Bellissant E, Sebille V, et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. British Journal of Clinical Pharmacology. 1998;46(6):589–597.
    1. Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. Journal of the American Medical Association. 2002;288(7):862–871.
    1. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. The New England Journal of Medicine. 2008;358(2):111–124.
    1. Annane D, Cariou A, Maxime V, et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. Journal of the American Medical Association. 2010;303(4):341–348.
    1. Hoen S, Mazoit J-X, Asehnoune K, et al. Hydrocortisone increases the sensitivity to α1- adrenoceptor stimulation in humans following hemorrhagic shock. Critical Care Medicine. 2005;33(12):2737–2743.
    1. Weis F, Beiras-Fernandez A, Schelling G, et al. Stress doses of hydrocortisone in high-risk patients undergoing cardiac surgery: effects on interleukin-6 to interleukin-10 ratio and early outcome. Critical Care Medicine. 2009;37(5):1685–1690.
    1. Fuchs PC, Bozkurt A, Johnen D, Smeets R, Groger A, Pallua N. Beneficial effect of corticosteroids in catecholamine-dependent septic burn patients. Burns. 2007;33(3):306–311.
    1. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95(5):1122–1125.
    1. Gordon AC, Wang N, Walley KR, Ashby D, Russell JA. The cardio-pulmonary effects of vasopressin compared to norepinephrine in septic shock. Chest. 2012;142(3):593–605.
    1. Russell JA, Walley KR, Gordon AC, et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine. 2009;37(3):811–818.
    1. Kampmeier TG, Rehberg S, Westphal M, Lange M. Vasopressin in sepsis and septic shock. Minerva Anestesiologica. 2010;76(10):844–850.
    1. Albanèse J, Leone M, Delmas A, Martin C. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Critical Care Medicine. 2005;33(9):1897–1902.
    1. Morelli A, Ertmer C, Lange M, et al. Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia. 2008;100(4):494–503.
    1. Lange M, Morelli A, Ertmer C, et al. Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock. 2007;28(5):623–629.
    1. Morelli A, Ertmer C, Rehberg S, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care. 2009;13(4, article R130)
    1. López A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Critical Care Medicine. 2004;32(1):21–30.
    1. Alexander JH, Reynolds HR, Stebbins AL, et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. Journal of the American Medical Association. 2007;297(15):1657–1666.
    1. Paciullo CA, Horner DM, Hatton KW, Flynn JD. Methylene blue for the treatment of septic shock. Pharmacotherapy. 2010;30(7):702–715.
    1. Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Critical Care Medicine. 2001;29(10):1860–1867.
    1. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Annals of Thoracic Surgery. 2004;77(2):496–499.
    1. Juffermans NP, Vervloet MG, Daemen-Gubbels CRG, Binnekade JM, Jong MD, Groeneveld ABJ. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. Nitric Oxide. 2010;22(4):275–280.
    1. Hollenberg SM. Vasoactive drugs in circulatory shock. American Journal of Respiratory and Critical Care Medicine. 2011;183(7):847–855.
    1. Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. The Lancet. 2007;370(9588):676–684.
    1. Mehta SR, Yusuf S, Díaz R, et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. Journal of the American Medical Association. 2005;293(4):437–446.
    1. Fan Y, Zhang A-M, Xiao Y-B, Weng Y-G, Hetzer R. Glucose-insulin-potassium therapy in adult patients undergoing cardiac surgery: a meta-analysis. European Journal of Cardio-thoracic Surgery. 2011;40(1):192–199.
    1. Howell NJ, Ashrafian H, Drury NE, et al. Glucose-insulin-potassium reduces the incidence of low cardiac output episodes after aortic valve replacement for aortic stenosis in patients with left ventricular hypertrophy: results from the hypertrophy, insulin, glucose, and electrolytes (HINGE) trial. Circulation. 2011;123(2):170–177.
    1. Hamdulay SS, Al-Khafaji A, Montgomery H. Glucose-insulin and potassium infusions in septic shock. Chest. 2006;129(3):800–804.
    1. Puskarich MA, Runyon MS, Trzeciak S, Kline JA, Jones AE. Review: effect of glucose-insulin-potassium infusion on mortality in critical care settings: a systematic review and meta-analysis. Journal of Clinical Pharmacology. 2009;49(7):758–767.
    1. Schortgen F, Clabault K, Katsahian S, et al. Fever control using external cooling in septic shock: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012;185(10):1088–1095.
    1. Honore PM, Jamez J, Wauthier M, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Critical Care Medicine. 2000;28(11):3581–3587.
    1. Cornejo R, Downey P, Castro R, et al. High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Medicine. 2006;32(5):713–722.
    1. Bréchot N, Luyt CE, Schmidt M, et al. Venoarterial extracorporeal membrane oxygenation support for refractory cardiovascular dysfunction during severe bacterial septic shock. Critical Care Medicine. 2013;41(7):1616–1626.
    1. Ronco C, Brendolan A, Lonnemann G, et al. A pilot study of coupled plasma filtration with adsorption in septic shock. Critical Care Medicine. 2002;30(6):1250–1255.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj